Novel K+ Channel Targets in Atrial Fibrillation Drug Development – Where Are We?

El-Haou, S.; Ford, J.; Milnes, J. Journal of Cardiovascular Pharmacology. 2015, 66 (5), 412-431


View
Recommended Publications
Latest Publications
Activation of TREK-1 and TREK-2 Two-Pore Domain Potassium Channels by the Kv4 Channel Modulator, NS5806

NS5806, widely used as a Kv4-selective activator, also activates TREK-1 and TREK-2 potassium channels.

Beyond Hybridisation: Biologically Meaningful Protein Interactions of Oligonucleotides

Nature Communications paper ‘The nucleobase guanine at the 3′-terminus of oligonucleotide RGLS4326 drives off-target AMPAR inhibition and CNS toxicity'

View All
Activation of TREK-1 and TREK-2 Two-Pore Domain Potassium Channels by the Kv4 Channel Modulator, NS5806
Future-proof cardiac safety: Scalable hiPSC cardiomyocyte new approach methodologies (NAMs) that de-risk earlier and strengthen IND packages
View All
Metrion is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
Copyright © 2024 Metrion. All rights reserved | Privacy notice | Registered as a company in England and Wales: 09669815 | VAT: GB 219828479
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram